measureName,qualityId,submissionMethod,measureType,benchmark,standardDeviation,average,decile1,decile2,decile3,decile4,decile5,decile6,decile7,decile8,decile9,decile10,isToppedOut,isToppedOutByProgram,percentile1,percentile10,percentile20,percentile30,percentile40,percentile50,percentile60,percentile70,percentile80,percentile90,percentile99,isHighPriority,isInverse,metricType
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,eCQM,Process,Y,21.041128922784218,82.51,6.41,52.985,70.175,80.36,86.32,90.91,93.75,96.045,98.0,99.55,No,No,6.41,52.985,70.175,80.36,86.32,90.91,93.75,96.045,98.0,99.55,100.0,Y,n,singlePerformanceRate
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,MIPS CQM,Process,Y,21.11901624495481,91.44,3.33,72.335,91.445,98.71,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,3.33,72.335,91.445,98.71,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,MIPS CQM,Process,Y,21.517188136839923,90.41,0.84,67.77,89.415,96.24,99.635,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.84,67.77,89.415,96.24,99.635,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients,322,MIPS CQM,Efficiency,Y,5.956521584349856,1.01,48.9,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,48.9,Y,y,singlePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,MIPS CQM,Process,Y,24.23069053225763,86.25,13.27,45.34,68.35,92.11,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,13.27,45.34,68.35,92.11,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,eCQM,Process,Y,6.898232842419116,4.67,0.01,0.12,0.25,0.46,0.93,1.87,3.02,4.79,7.89,11.86,No,No,0.01,0.12,0.25,0.46,0.93,1.87,3.02,4.79,7.89,11.86,35.04,N,n,singlePerformanceRate
Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer,450,MIPS CQM,Process,Y,23.83151436595648,67.40,30.0,39.39,42.405,50.0,54.42,63.3,78.18,87.8,95.89,100.0,No,No,30.0,39.39,42.405,50.0,54.42,63.3,78.18,87.8,95.89,100.0,100.0,Y,n,singlePerformanceRate
ED Median Time from ED arrival to ED departure for all Adult Patients,ACEP50,QCDR Measure,Outcome,Y,18.456835453349964,104.87,155.995,127.228,117.9865,111.896,106.929,103.0555,98.8234,94.6961,90.0213,84.3452,No,No,58.637,84.3452,90.0213,94.6961,98.8234,103.0555,106.929,111.896,117.9865,127.228,155.995,Y,y,nonProportion
Appropriate Emergency Department Utilization of Lumbar Spine Imaging for Atraumatic Low Back Pain,ACEP52,QCDR Measure,Process,Y,21.355022430173122,52.69,5.17,12.73,21.43,54.25,59.18,62.99,64.35,66.58,67.73,70.88,No,No,5.17,12.73,21.43,54.25,59.18,62.99,64.35,66.58,67.73,70.88,75.0,Y,n,registrySinglePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,MIPS CQM,Outcome,Y,11.732584357821485,94.96,23.55,85.71,92.91,97.03,98.36,99.18,100.0,100.0,100.0,100.0,No,No,23.55,85.71,92.91,97.03,98.36,99.18,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,eCQM,Outcome,Y,15.381644439994288,90.96,17.24,74.48,88.08,92.67,95.14,96.765,97.86,98.63,99.27,100.0,No,No,17.24,74.48,88.08,92.67,95.14,96.765,97.86,98.63,99.27,100.0,100.0,Y,n,singlePerformanceRate
Dementia: Education and Support of Caregivers for Patients with Dementia,288,MIPS CQM,Process,Y,29.133935212919084,84.42,1.19,27.36,76.855,91.31,98.615,100.0,100.0,100.0,100.0,100.0,Yes,Yes,1.19,27.36,76.855,91.31,98.615,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Chlamydia Screening for Women,310,eCQM,Process,Y,19.073136873501237,36.20,1.35,11.11,18.255,25.0,30.0,35.48,40.865,45.48,53.015,61.9,No,No,1.35,11.11,18.255,25.0,30.0,35.48,40.865,45.48,53.015,61.9,82.43,N,n,singlePerformanceRate
Non-Muscle Invasive Bladder Cancer: Early Surveillance Cystoscopy for Non-Muscle Invasive Bladder Cancer,AQUA18,QCDR Measure,Process,Y,11.16315384899729,27.30,1.67,15.54,18.37,21.62,24.24,27.59,28.12,31.25,35.0,41.43,No,No,1.67,15.54,18.37,21.62,24.24,27.59,28.12,31.25,35.0,41.43,66.67,N,n,registrySinglePerformanceRate
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,QCDR Measure,Outcome,Y,9.760034259441142,87.99,56.86,80.44,84.62,86.52,88.02,89.415,90.37,92.06,93.83,96.36,No,No,56.86,80.44,84.62,86.52,88.02,89.415,90.37,92.06,93.83,96.36,100.0,Y,n,registrySinglePerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,MIPS CQM,Process,Y,10.087306916925085,96.46,38.46,91.21,96.97,98.86,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,38.46,91.21,96.97,98.86,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),008,eCQM,Process,Y,10.567778670742372,89.71,42.86,80.49,85.71,88.52,90.7,92.31,93.64,95.0,96.39,98.15,No,No,42.86,80.49,85.71,88.52,90.7,92.31,93.64,95.0,96.39,98.15,100.0,N,n,singlePerformanceRate
Functional Status Change for Patients with Hip Impairments,218,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,20.375161466795298,56.81,17.36,35.71,41.525,46.13,49.395,53.375,56.64,59.98,69.225,95.225,No,No,17.36,35.71,41.525,46.13,49.395,53.375,56.64,59.98,69.225,95.225,100.0,Y,n,singlePerformanceRate
Multimodal Pain Management,477,MIPS CQM,Process,Y,8.171177789253234,95.61,62.56,86.39,94.17,96.64,97.96,98.77,99.49,99.99,100.0,100.0,Yes,Yes,62.56,86.39,94.17,96.64,97.96,98.77,99.49,99.99,100.0,100.0,100.0,Y,n,singlePerformanceRate
Functional Status Change for Patients with Neck Impairments,478,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,19.73709916443881,56.05,22.5,33.61,40.0,44.44,50.0,53.33,57.45,61.97,66.67,89.66,No,No,22.5,33.61,40.0,44.44,50.0,53.33,57.45,61.97,66.67,89.66,100.0,Y,n,singlePerformanceRate
Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS43,QCDR Measure,Outcome,Y,31.114322532664385,37.99,5.0,8.7,14.29,17.42,21.62,24.35,31.67,36.17,77.59,93.33,No,No,5.0,8.7,14.29,17.42,21.62,24.35,31.67,36.17,77.59,93.33,100.0,Y,n,registrySinglePerformanceRate
Diabetic Foot Ulcer (DFU) Healing or Closure,CDR2,QCDR Measure,Outcome,Y,8.46129408981975,17.32,4.0,7.69,11.54,13.21,14.77,16.89,19.05,19.7,22.61,24.44,No,No,4.0,7.69,11.54,13.21,14.77,16.89,19.05,19.7,22.61,24.44,57.45,Y,n,registryMultiPerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,MIPS CQM,Process,Y,26.985705063092077,82.95,2.28,31.82,64.94,85.33,94.62,98.35,99.72,100.0,100.0,100.0,Yes,No,2.28,31.82,64.94,85.33,94.62,98.35,99.72,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Medicare Part B Claims,Process,Y,18.69544302877808,92.43,14.71,66.67,95.78,99.26,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,14.71,66.67,95.78,99.26,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Barrett's Esophagus,249,Medicare Part B Claims,Process,Y,0.34762130315902884,99.95,97.5,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,97.5,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Barrett's Esophagus,249,MIPS CQM,Process,Y,0.9638649033209042,99.88,96.25,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,96.25,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Surgical Site Infection (SSI),357,MIPS CQM,Outcome,Y,13.736208352619212,3.80,80.06,6.34,1.17,0.0,0.0,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.17,6.34,80.06,Y,y,singlePerformanceRate
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,MIPS CQM,Process,Y,22.425762414997156,91.36,5.01,56.1,98.48,99.85,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,5.01,56.1,98.48,99.85,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,eCQM,Process,Y,32.067478861768606,39.30,0.62,2.94,7.31,13.66,20.79,33.94,43.41,54.6,71.205,93.41,No,No,0.62,2.94,7.31,13.66,20.79,33.94,43.41,54.6,71.205,93.41,100.0,Y,n,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,MIPS CQM,Efficiency,Y,10.590722796342007,6.81,52.38,20.0,13.51,7.04,3.85,1.985,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,1.985,3.85,7.04,13.51,20.0,52.38,Y,y,singlePerformanceRate
Age Appropriate Screening Colonoscopy,439,MIPS CQM,Efficiency,Y,0.4297072215028373,0.14,1.96,0.28,0.07,0.0,0.0,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.07,0.28,1.96,Y,y,singlePerformanceRate
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,ACEP55,QCDR Measure,Process,Y,18.464212071281924,64.08,24.14,37.31,46.43,55.38,60.0,69.88,73.77,77.03,81.43,84.05,No,No,24.14,37.31,46.43,55.38,60.0,69.88,73.77,77.03,81.43,84.05,91.95,Y,n,registrySinglePerformanceRate
Gout: Serum Urate Target,ACR14,QCDR Measure,Intermediate Outcome,Y,12.955373394021342,47.78,17.24,30.0,38.46,43.24,45.21,46.58,50.0,52.38,58.97,65.22,No,No,17.24,30.0,38.46,43.24,45.21,46.58,50.0,52.38,58.97,65.22,80.39,Y,n,registrySinglePerformanceRate
Regaining Vision After Cataract Surgery,IRIS59,QCDR Measure,Outcome,Y,19.604095063739486,39.66,1.3699,16.3265,23.6679,28.3168,32.1839,35.6306,42.7874,49.3119,56.7458,67.3469,No,No,1.3699,16.3265,23.6679,28.3168,32.1839,35.6306,42.7874,49.3119,56.7458,67.3469,85.5219,Y,n,registryMultiPerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with low back pain.",IROMS18,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,6.9811406155266855,48.08,61.11,55.42,53.45,52.05,50.85,49.965,47.59,45.45,42.86,39.08,No,No,26.87,39.08,42.86,45.45,47.59,49.965,50.85,52.05,53.45,55.42,61.11,Y,y,registryMultiPerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,MIPS CQM,Process,Y,15.513982446041645,93.05,20.27,74.86,94.89,97.55,98.72,99.31,99.9,100.0,100.0,100.0,Yes,Yes,20.27,74.86,94.89,97.55,98.72,99.31,99.9,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Oncology: Medical and Radiation - Pain Intensity Quantified,143,eCQM,Process,Y,26.33112244141306,84.94,2.31,43.535,79.995,90.645,94.685,96.89,98.015,98.92,99.64,100.0,Yes,Yes,2.31,43.535,79.995,90.645,94.685,96.89,98.015,98.92,99.64,100.0,100.0,Y,n,singlePerformanceRate
Medication Prescribed For Acute Migraine Attack,AAN5,QCDR Measure,Process,Y,15.599916457360324,73.96,40.74,50.85,57.14,66.84,71.09,77.2,80.65,81.82,86.67,95.31,No,No,40.74,50.85,57.14,66.84,71.09,77.2,80.65,81.82,86.67,95.31,98.15,N,n,registrySinglePerformanceRate
COPD: Steroids for no more than 5 days in COPD Exacerbation,ACQR3,QCDR Measure,Efficiency,Y,0.03719083078847314,0.96,0.85,0.915,0.945,0.96,0.97,0.97,0.975,0.985,0.995,1.0,Yes,No,0.85,0.915,0.945,0.96,0.97,0.97,0.975,0.985,0.995,1.0,1.0,Y,n,registrySinglePerformanceRate
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,QCDR Measure,Outcome,Y,7.350114110850846,4.79,37.38,10.37,5.795,4.11,3.275,2.82,2.29,1.8,1.38,0.95,No,No,0.2,0.95,1.38,1.8,2.29,2.82,3.275,4.11,5.795,10.37,37.38,Y,y,nonProportion
Report Turnaround Time: MRI,ACRAD17,QCDR Measure,Outcome,Y,8.957920312288573,10.34,46.09,21.19,15.39,12.8,10.44,8.19,6.06,4.4,3.24,2.14,No,No,0.54,2.14,3.24,4.4,6.06,8.19,10.44,12.8,15.39,21.19,46.09,Y,y,nonProportion
Perioperative Anemia Management,AQI72,QCDR Measure,Process,Y,2.4951835886645997,98.79,89.61,94.95,98.11,99.84,100.0,100.0,100.0,100.0,100.0,100.0,Yes,No,89.61,94.95,98.11,99.84,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with knee injury pain.",IROMS12,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,6.5486472269646505,50.59,63.11,57.69,55.06,53.79,52.17,50.88,50.0,48.28,46.88,43.75,No,No,24.91,43.75,46.88,48.28,50.0,50.88,52.17,53.79,55.06,57.69,63.11,Y,y,registryMultiPerformanceRate
Anti-Depressant Medication Management,009,eCQM,Process,Y,12.618140857074616,77.50,25.0,62.22,71.33,75.56,77.78,80.205,82.26,83.82,85.68,88.49,No,No,25.0,62.22,71.33,75.56,77.78,80.205,82.26,83.82,85.68,88.49,100.0,N,n,multiPerformanceRate
Colorectal Cancer Screening,113,MIPS CQM,Process,Y,33.09770061124736,56.97,0.3,4.555,18.09,37.7,52.67,63.665,72.415,80.945,90.25,99.55,No,No,0.3,4.555,18.09,37.7,52.67,63.665,72.415,80.945,90.25,99.55,100.0,N,n,singlePerformanceRate
Colorectal Cancer Screening,113,eCQM,Process,Y,27.33627125472049,49.64,0.18,7.22,22.61,34.53,43.9,51.89,59.65,66.98,75.51,85.69,No,No,0.18,7.22,22.61,34.53,43.9,51.89,59.65,66.98,75.51,85.69,99.04,N,n,singlePerformanceRate
Colorectal Cancer Screening,113,Medicare Part B Claims,Process,Y,25.39240010359504,82.47,3.64,38.16,68.98,80.27,88.17,95.67,98.73,100.0,100.0,100.0,Yes,No,3.64,38.16,68.98,80.27,88.17,95.67,98.73,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),118,MIPS CQM,Process,Y,11.048073292413394,84.59,55.56,70.69,76.67,79.62,82.09,84.96,87.5,90.32,96.15,100.0,No,No,55.56,70.69,76.67,79.62,82.09,84.96,87.5,90.32,96.15,100.0,100.0,N,n,singlePerformanceRate
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,MIPS CQM,Process,Y,10.475743881047183,95.43,53.33,85.45,93.875,97.385,99.44,100.0,100.0,100.0,100.0,100.0,Yes,Yes,53.33,85.45,93.875,97.385,99.44,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Childhood Immunization Status,240,eCQM,Process,Y,17.718391614572504,38.78,1.75,13.1,22.58,31.01,36.67,40.48,43.54,49.17,53.59,59.96,No,No,1.75,13.1,22.58,31.01,36.67,40.48,43.54,49.17,53.59,59.96,81.48,N,n,singlePerformanceRate
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,MIPS CQM,Process,Y,37.24278567067983,57.48,1.03,6.97,10.94,30.14,40.91,55.78,80.0,91.67,99.38,100.0,No,No,1.03,6.97,10.94,30.14,40.91,55.78,80.0,91.67,99.38,100.0,100.0,N,n,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,MIPS CQM,Process,Y,11.160155893721681,4.48,50.0,13.04,6.06,2.43,0.0,0.0,0.0,0.0,0.0,0.0,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,2.43,6.06,13.04,50.0,Y,y,singlePerformanceRate
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,MIPS CQM,Process,Y,4.584934545913668,98.94,76.53,98.39,99.665,99.825,99.93,99.99,100.0,100.0,100.0,100.0,Yes,Yes,76.53,98.39,99.665,99.825,99.93,99.99,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Report Turnaround Time: Mammography,ACRAD25,QCDR Measure,Outcome,Y,24.894478627214866,18.53,154.68,46.495,27.765,21.2,16.455,11.85,6.815,4.165,2.195,0.595,No,No,0.0,0.595,2.195,4.165,6.815,11.85,16.455,21.2,27.765,46.495,154.68,Y,y,nonProportion
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,048,MIPS CQM,Process,Y,28.275480802398143,79.44,0.32,32.46,58.07,74.83,85.25,95.01,98.39,99.7,100.0,100.0,Yes,No,0.32,32.46,58.07,74.83,85.25,95.01,98.39,99.7,100.0,100.0,100.0,N,n,singlePerformanceRate
Initiation and Engagement of Substance Use Disorder Treatment,305,eCQM,Process,Y,6.03812912982253,5.13,0.34,1.06,1.65,2.17,2.7,3.35,4.23,5.18,6.67,10.16,No,No,0.34,1.06,1.65,2.17,2.7,3.35,4.23,5.18,6.67,10.16,33.91,Y,n,multiPerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,MIPS CQM,Outcome,Y,5.596153453125839,96.82,75.76,89.14,95.1,96.77,98.26,100.0,100.0,100.0,100.0,100.0,Yes,Yes,75.76,89.14,95.1,96.77,98.26,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,MIPS CQM,Intermediate Outcome,Y,16.668455743499933,42.07,4.35,18.18,26.985,34.19,40.735,44.23,47.615,50.89,54.49,59.38,No,No,4.35,18.18,26.985,34.19,40.735,44.23,47.615,50.89,54.49,59.38,82.18,Y,n,singlePerformanceRate
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,QCDR Measure,Process,Y,19.31823897046145,53.50,22.52,28.47,34.8,40.73,48.42,54.26,57.68,62.63,70.5,79.76,No,No,22.52,28.47,34.8,40.73,48.42,54.26,57.68,62.63,70.5,79.76,95.07,Y,n,registrySinglePerformanceRate
ED Median Time from ED arrival to ED departure for all Pediatric ED Patients,ACEP51,QCDR Measure,Outcome,Y,17.565387445310293,96.28,147.395,114.921,107.823,104.667,99.7479,95.5479,91.5498,86.6811,83.3691,76.1444,No,No,57.6641,76.1444,83.3691,86.6811,91.5498,95.5479,99.7479,104.667,107.823,114.921,147.395,Y,y,nonProportion
Report Turnaround Time: PET,ACRAD19,QCDR Measure,Outcome,Y,12.964531597651998,13.95,66.65,31.9,24.2,19.16,13.09,9.96,6.99,4.77,3.41,2.54,No,No,0.0,2.54,3.41,4.77,6.99,9.96,13.09,19.16,24.2,31.9,66.65,Y,y,nonProportion
Screening Coronary Calcium Scoring for Cardiovascular Risk Assessment Including Coronary Artery Calcification Regional Distribution Scoring,MSN13,QCDR Measure,Process,Y,23.610009311360713,82.39,26.0,35.0,71.0,79.0,87.0,94.0,96.0,99.0,100.0,100.0,No,No,26.0,35.0,71.0,79.0,87.0,94.0,96.0,99.0,100.0,100.0,100.0,N,n,registrySinglePerformanceRate
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,MIPS CQM,Process,Y,31.243534576552793,30.23,96.32,81.08,64.645,46.945,32.11,17.725,8.0,3.755,0.39,0.0,No,No,0.0,0.0,0.39,3.755,8.0,17.725,32.11,46.945,64.645,81.08,96.32,Y,y,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Medicare Part B Claims,Process,Y,40.762394310116775,59.57,0.71,2.08,6.12,23.81,46.07,70.46,96.3,100.0,100.0,100.0,No,No,0.71,2.08,6.12,23.81,46.07,70.46,96.3,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,MIPS CQM,Process,Y,39.607440820103534,69.81,0.51,3.83,14.5,50.0,87.225,99.49,100.0,100.0,100.0,100.0,Yes,Yes,0.51,3.83,14.5,50.0,87.225,99.49,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Stones: Urinalysis Performed Before Surgical Stone Procedures,AQUA15,QCDR Measure,Process,Y,24.952754012838877,66.87,4.17,26.27,47.22,55.77,65.09,73.47,79.31,85.19,87.76,94.44,No,No,4.17,26.27,47.22,55.77,65.09,73.47,79.31,85.19,87.76,94.44,100.0,Y,n,registrySinglePerformanceRate
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,QCDR Measure,Process,Y,14.772063743006235,93.36,13.3,80.89,93.75,96.67,97.65,98.355,98.9,99.25,99.67,100.0,Yes,No,13.3,80.89,93.75,96.67,97.65,98.355,98.9,99.25,99.67,100.0,100.0,Y,n,registrySinglePerformanceRate
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs,PIMSH10,QCDR Measure,Process,Y,24.274324458614245,49.66,2.4,20.8,27.6,35.0,41.2,47.95,57.1,64.5,69.6,85.2,No,No,2.4,20.8,27.6,35.0,41.2,47.95,57.1,64.5,69.6,85.2,95.2,Y,n,registrySinglePerformanceRate
Arteriovenous Graft Thrombectomy Success Rate,RPAQIR14,QCDR Measure,Outcome,Y,7.145437402684011,85.33,69.37,72.97,79.29,81.58,83.91,86.83,88.57,90.85,91.98,93.1,Yes,No,69.37,72.97,79.29,81.58,83.91,86.83,88.57,90.85,91.98,93.1,95.36,Y,n,registrySinglePerformanceRate
Coronary Artery Disease (CAD): Antiplatelet Therapy,006,MIPS CQM,Process,Y,13.16499295115252,87.37,41.67,70.83,77.71,83.02,86.8,90.4,93.66,97.04,100.0,100.0,No,No,41.67,70.83,77.71,83.02,86.8,90.4,93.66,97.04,100.0,100.0,100.0,N,n,singlePerformanceRate
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,050,MIPS CQM,Process,Y,23.660527840546795,79.11,1.7,46.96,68.25,75.18,80.62,83.8,88.46,96.97,100.0,100.0,No,No,1.7,46.96,68.25,75.18,80.62,83.8,88.46,96.97,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Testing for Pharyngitis,066,MIPS CQM,Process,Y,14.551126394236267,91.64,26.09,76.92,86.89,92.0,95.45,97.64,98.9,100.0,100.0,100.0,Yes,No,26.09,76.92,86.89,92.0,95.45,97.64,98.9,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Testing for Pharyngitis,066,eCQM,Process,Y,29.56022345569818,55.71,0.54,7.41,22.0,36.8,52.43,63.82,72.73,80.0,84.11,88.42,No,No,0.54,7.41,22.0,36.8,52.43,63.82,72.73,80.0,84.11,88.42,96.24,Y,n,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Medicare Part B Claims,Outcome,Y,14.050686767984585,96.43,8.57,95.77,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,No,No,8.57,95.77,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,MIPS CQM,Outcome,Y,22.83437623073675,85.64,1.39,52.27,75.17,86.31,93.41,96.255,98.26,99.38,100.0,100.0,No,No,1.39,52.27,75.17,86.31,93.41,96.255,98.26,99.38,100.0,100.0,100.0,Y,n,singlePerformanceRate
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,MIPS CQM,Process,Y,30.605211717472788,40.23,0.69,5.16,11.24,18.09,26.98,32.975,38.35,51.92,64.58,95.05,No,No,0.69,5.16,11.24,18.09,26.98,32.975,38.35,51.92,64.58,95.05,100.0,Y,n,singlePerformanceRate
Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines,AAO23,QCDR Measure,Process,Y,20.155537129103678,71.58,3.98,47.15,59.87,67.38,72.36,77.105,80.43,83.77,84.91,90.59,No,No,3.98,47.15,59.87,67.38,72.36,77.105,80.43,83.77,84.91,90.59,98.94,N,n,registrySinglePerformanceRate
Avoidance of Opiates for Low Back Pain or Migraines,ECPR46,QCDR Measure,Process,Y,4.434916864507268,98.17,80.66,92.32,99.31,99.69,99.9,100.0,100.0,100.0,100.0,100.0,Yes,Yes,80.66,92.32,99.31,99.69,99.9,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Preventive Care and Screening: Influenza Immunization,110,eCQM,Process,Y,27.006976451195857,43.92,0.19,5.33,17.7,27.74,36.15,43.91,51.19,58.14,67.23,82.04,No,No,0.19,5.33,17.7,27.74,36.15,43.91,51.19,58.14,67.23,82.04,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Influenza Immunization,110,MIPS CQM,Process,Y,30.718989218776738,70.41,0.51,18.67,40.36,57.41,68.37,81.415,90.6,96.17,99.37,100.0,No,No,0.51,18.67,40.36,57.41,68.37,81.415,90.6,96.17,99.37,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Influenza Immunization,110,Medicare Part B Claims,Process,Y,27.397529029668313,82.19,1.57,30.56,69.89,81.29,90.18,96.83,99.33,100.0,100.0,100.0,Yes,No,1.57,30.56,69.89,81.29,90.18,96.83,99.33,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Falls: Plan of Care,155,Medicare Part B Claims,Process,Y,19.677567441821683,93.14,3.85,75.0,97.895,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,3.85,75.0,97.895,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Falls: Plan of Care,155,MIPS CQM,Process,Y,19.240811835858967,93.27,3.07,80.68,97.06,99.71,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,3.07,80.68,97.06,99.71,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,MIPS CQM,Efficiency,Y,5.651780275079506,0.81,50.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,50.0,Y,y,singlePerformanceRate
HIV Viral Load Suppression,338,MIPS CQM,Outcome,Y,9.493739829274125,92.25,57.32,81.74,87.33,91.32,93.26,94.495,95.82,98.98,100.0,100.0,No,No,57.32,81.74,87.33,91.32,93.26,94.495,95.82,98.98,100.0,100.0,100.0,Y,n,singlePerformanceRate
Chronic Anterior Uveitis - Post-treatment visual acuity,IRIS53,QCDR Measure,Outcome,Y,9.52048256413341,89.60,53.12,78.69,84.0,86.36,88.24,90.18,92.86,95.24,97.78,100.0,No,No,53.12,78.69,84.0,86.36,88.24,90.18,92.86,95.24,97.78,100.0,100.0,Y,n,registrySinglePerformanceRate
Oncology: Utilization of GCSF in Metastatic Colorectal Cancer,PIMSH2,QCDR Measure,Efficiency,Y,16.345983781062277,24.79,67.7,40.0,36.8,35.2,31.4,25.0,23.0,10.5,4.8,4.0,No,No,3.7,4.0,4.8,10.5,23.0,25.0,31.4,35.2,36.8,40.0,67.7,Y,y,registrySinglePerformanceRate
Documentation of Current Medications in the Medical Record,130,eCQM,Process,Y,18.52644311286649,88.50,7.66,66.25,83.08,89.82,93.63,96.12,97.75,98.79,99.47,99.87,Yes,Yes,7.66,66.25,83.08,89.82,93.63,96.12,97.75,98.79,99.47,99.87,100.0,Y,n,singlePerformanceRate
Documentation of Current Medications in the Medical Record,130,MIPS CQM,Process,Y,28.24144350856547,86.45,2.6,30.29,87.26,95.57,98.62,99.74,99.99,100.0,100.0,100.0,Yes,Yes,2.6,30.29,87.26,95.57,98.62,99.74,99.99,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management,283,MIPS CQM,Process,Y,18.988351617347483,94.27,2.94,89.86,98.59,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,2.94,89.86,98.59,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,MIPS CQM,Process,Y,28.768843484017122,82.71,0.9,30.43,66.94,84.38,95.12,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.9,30.43,66.94,84.38,95.12,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Closing the Referral Loop: Receipt of Specialist Report,374,eCQM,Process,Y,28.897564140069345,37.92,0.5,4.85,11.36,17.31,23.48,30.5,38.83,50.51,66.57,85.71,No,No,0.5,4.85,11.36,17.31,23.48,30.5,38.83,50.51,66.57,85.71,100.0,Y,n,singlePerformanceRate
Psoriasis: Clinical Response to Systemic Medications,410,MIPS CQM,Outcome,Y,23.947183175270133,84.82,4.55,45.495,70.135,85.19,93.455,97.56,100.0,100.0,100.0,100.0,No,No,4.55,45.495,70.135,85.19,93.455,97.56,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,MIPS CQM,Efficiency,Y,3.681525500848706,97.66,81.7,93.94,96.31,97.54,98.33,98.94,99.39,100.0,100.0,100.0,Yes,No,81.7,93.94,96.31,97.54,98.33,98.94,99.39,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Visual Field Progression in Glaucoma,IRIS44,QCDR Measure,Outcome,Y,16.804560315123254,12.29,90.0,18.18,13.33,12.64,11.63,11.125,7.14,5.0,4.05,1.39,No,No,0.0,1.39,4.05,5.0,7.14,11.125,11.63,12.64,13.33,18.18,90.0,Y,y,registrySinglePerformanceRate
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,MIPS CQM,Process,Y,38.71869055183531,71.83,0.04,1.35,31.62,64.15,83.1,98.08,100.0,100.0,100.0,100.0,Yes,No,0.04,1.35,31.62,64.15,83.1,98.08,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Rheumatoid Arthritis (RA): Functional Status Assessment,178,MIPS CQM,Process,Y,20.468391008250155,90.90,1.34,74.61,89.38,95.11,98.44,99.54,100.0,100.0,100.0,100.0,Yes,Yes,1.34,74.61,89.38,95.11,98.44,99.54,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,MIPS CQM,Process,Y,31.978937386642052,70.55,2.88,17.3,34.62,53.74,72.0,84.85,92.86,97.78,100.0,100.0,No,No,2.88,17.3,34.62,53.74,72.0,84.85,92.86,97.78,100.0,100.0,100.0,N,n,multiPerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,eCQM,Process,Y,31.194528914569652,58.23,2.05,13.95,25.0,36.11,48.0,60.36,72.5,84.0,92.31,98.33,No,No,2.05,13.95,25.0,36.11,48.0,60.36,72.5,84.0,92.31,98.33,100.0,N,n,multiPerformanceRate
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Medicare Part B Claims,Process,Y,19.62781530451412,91.22,5.38,68.18,90.2,96.43,100.0,100.0,100.0,100.0,100.0,100.0,Yes,No,5.38,68.18,90.2,96.43,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,multiPerformanceRate
Radical Prostatectomy Pathology Reporting,250,MIPS CQM,Process,Y,0.5600639975360316,99.93,97.78,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,97.78,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Radical Prostatectomy Pathology Reporting,250,Medicare Part B Claims,Process,Y,9.116360750504192,98.68,36.84,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,36.84,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Falls: Screening for Future Fall Risk,318,eCQM,Process,Y,34.97452159145642,58.76,0.14,3.91,16.8,35.7,52.47,66.87,79.39,88.69,95.37,98.92,No,No,0.14,3.91,16.8,35.7,52.47,66.87,79.39,88.69,95.37,98.92,100.0,Y,n,singlePerformanceRate
HIV Medical Visit Frequency,340,MIPS CQM,Process,Y,23.078181307493413,78.11,27.94,38.46,51.22,73.26,79.63,84.39,90.68,93.43,100.0,100.0,No,No,27.94,38.46,51.22,73.26,79.63,84.39,90.68,93.43,100.0,100.0,100.0,Y,n,singlePerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Medicare Part B Claims,Process,Y,2.035114423865602,99.10,91.3,95.83,98.11,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,91.3,95.83,98.11,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,MIPS CQM,Process,Y,6.405242683424638,99.44,88.03,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,88.03,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,MIPS CQM,Outcome,Y,27.502586076750877,51.32,6.52,16.81,21.9,34.78,38.78,56.94,62.28,64.71,77.29,81.48,No,No,6.52,16.81,21.9,34.78,38.78,56.94,62.28,64.71,77.29,81.48,100.0,Y,n,singlePerformanceRate
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture,472,eCQM,Process,Y,3.8841871763330356,1.16,12.5,4.1,1.74,0.0,0.0,0.0,0.0,0.0,0.0,0.0,Yes,Yes,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.74,4.1,12.5,Y,y,singlePerformanceRate
Avoidance of Cerebral Hyperthermia for Procedures Involving Cardiopulmonary Bypass,AQI65,QCDR Measure,Outcome,Y,22.215748636145207,86.98,20.83,56.38,81.7,90.37,97.2,98.32,99.22,99.84,100.0,100.0,No,No,20.83,56.38,81.7,90.37,97.2,98.32,99.22,99.84,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Turnaround Time (TAT) - Biopsies,CAP22,QCDR Measure,Process,Y,9.624840991027543,91.27,68.5,70.85,87.24,90.61,93.5,94.41,95.68,96.07,99.47,100.0,No,No,68.5,70.85,87.24,90.61,93.5,94.41,95.68,96.07,99.47,100.0,100.0,Y,n,registrySinglePerformanceRate
Glaucoma – Intraocular Pressure Reduction,IRIS2,QCDR Measure,Intermediate Outcome,Y,17.5623092011299,71.09,1.8,50.93,61.7,66.91,71.09,74.29,77.61,80.13,83.5,87.59,No,No,1.8,50.93,61.7,66.91,71.09,74.29,77.61,80.13,83.5,87.59,100.0,Y,n,registrySinglePerformanceRate
Oncology: Advance Care Planning in Metastatic Cancer Patients,PIMSH1,QCDR Measure,Patient Engagement/Experience,Y,24.992942127219642,27.80,0.5,2.3,6.4,12.8,15.7,20.85,25.0,35.6,43.3,63.2,No,No,0.5,2.3,6.4,12.8,15.7,20.85,25.0,35.6,43.3,63.2,98.9,Y,n,registrySinglePerformanceRate
Appropriate Treatment for Upper Respiratory Infection (URI),065,eCQM,Process,Y,12.23165457700652,90.92,37.1,77.5,86.67,90.12,92.8,94.74,96.26,97.78,99.25,100.0,No,No,37.1,77.5,86.67,90.12,92.8,94.74,96.26,97.78,99.25,100.0,100.0,Y,n,singlePerformanceRate
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Medicare Part B Claims,Process,Y,23.110341127576785,87.58,10.34,51.415,78.685,93.295,97.405,100.0,100.0,100.0,100.0,100.0,Yes,Yes,10.34,51.415,78.685,93.295,97.405,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,MIPS CQM,Process,Y,10.061245476846427,97.65,33.94,96.11,99.875,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,33.94,96.11,99.875,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use,185,MIPS CQM,Process,Y,22.38658398957506,91.59,0.35,73.33,95.74,98.27,99.74,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.35,73.33,95.74,98.27,99.74,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Cataract Surgery: Difference Between Planned and Final Refraction,389,MIPS CQM,Outcome,Y,35.040244662851634,62.21,1.35,14.83,24.11,33.08,45.01,64.67,91.13,98.0,100.0,100.0,No,No,1.35,14.83,24.11,33.08,45.01,64.67,91.13,98.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Medicare Part B Claims,Process,Y,17.293343029597217,94.53,1.29,88.43,97.16,99.05,99.79,100.0,100.0,100.0,100.0,100.0,Yes,Yes,1.29,88.43,97.16,99.05,99.79,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,MIPS CQM,Process,Y,11.52113457741414,97.85,20.53,98.96,99.87,99.99,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,20.53,98.96,99.87,99.99,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,QCDR Measure,Process,Y,4.995791651472669,5.76,23.03,11.65,8.44,7.14,5.08,4.17,3.36,2.64,2.05,1.22,Yes,No,0.27,1.22,2.05,2.64,3.36,4.17,5.08,7.14,8.44,11.65,23.03,Y,y,registrySinglePerformanceRate
Hepatitis B Safety Screening,ACR10,QCDR Measure,Process,Y,15.926749204142071,29.52,4.35,6.98,13.33,20.37,23.62,30.35,34.38,36.01,41.06,55.25,No,No,4.35,6.98,13.33,20.37,23.62,30.35,34.38,36.01,41.06,55.25,63.2,Y,n,registrySinglePerformanceRate
Tunneled Hemodialysis Catheter Success,RCOIR12,QCDR Measure,Outcome,Y,10.311630597384832,76.96,52.94,60.925,68.815,72.225,76.27,79.38,80.86,82.92,86.28,88.105,No,No,52.94,60.925,68.815,72.225,76.27,79.38,80.86,82.92,86.28,88.105,95.74,Y,n,registrySinglePerformanceRate
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,014,MIPS CQM,Process,Y,18.09394940473038,91.06,5.91,74.55,89.16,93.79,96.31,98.075,99.14,99.77,100.0,100.0,Yes,Yes,5.91,74.55,89.16,93.79,96.31,98.075,99.14,99.77,100.0,100.0,100.0,N,n,singlePerformanceRate
Oncology: Medical and Radiation - Plan of Care for Pain,144,MIPS CQM,Process,Y,30.626744030146963,74.59,4.0,18.42,44.62,68.21,80.88,90.435,94.6,97.63,99.7,100.0,No,No,4.0,18.42,44.62,68.21,80.88,90.435,94.6,97.63,99.7,100.0,100.0,Y,n,singlePerformanceRate
Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy,176,MIPS CQM,Process,Y,24.44156567480802,84.43,1.35,47.06,66.67,84.52,95.33,98.01,100.0,100.0,100.0,100.0,Yes,Yes,1.35,47.06,66.67,84.52,95.33,98.01,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,MIPS CQM,Process,Y,21.838778565297204,87.53,1.68,63.035,78.8,89.195,94.315,98.755,100.0,100.0,100.0,100.0,Yes,No,1.68,63.035,78.8,89.195,94.315,98.755,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Functional Outcome Assessment,182,MIPS CQM,Process,Y,18.213445306893366,95.56,2.06,97.89,99.55,99.92,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,2.06,97.89,99.55,99.92,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,19.423332827567904,61.67,21.43,37.04,44.44,49.4,53.48,60.34,67.27,72.0,78.57,87.27,No,No,21.43,37.04,44.44,49.4,53.48,60.34,67.27,72.0,78.57,87.27,100.0,Y,n,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,MIPS CQM,Process,Y,35.09035897323816,55.98,0.05,12.04,21.49,28.33,35.87,50.25,71.53,91.76,98.69,100.0,No,No,0.05,12.04,21.49,28.33,35.87,50.25,71.53,91.76,98.69,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Medicare Part B Claims,Process,Y,28.23357126894443,86.22,0.32,31.91,84.62,96.66,99.04,99.73,100.0,100.0,100.0,100.0,Yes,No,0.32,31.91,84.62,96.66,99.04,99.73,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,eCQM,Process,Y,18.652964006940724,26.47,0.06,5.78,13.7,17.68,21.05,23.96,27.1,30.59,35.34,44.34,No,No,0.06,5.78,13.7,17.68,21.05,23.96,27.1,30.59,35.34,44.34,100.0,N,n,singlePerformanceRate
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,MIPS CQM,Process,Y,15.540596697334603,87.56,38.0,67.08,74.32,80.65,86.11,96.15,99.69,100.0,100.0,100.0,Yes,No,38.0,67.08,74.32,80.65,86.11,96.15,99.69,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Optimal Asthma Control,398,MIPS CQM,Outcome,Y,26.15120065596032,76.48,4.44,41.94,52.27,61.29,69.7,85.71,97.06,100.0,100.0,100.0,No,No,4.44,41.94,52.27,61.29,69.7,85.71,97.06,100.0,100.0,100.0,100.0,Y,n,multiPerformanceRate
Disease Activity Measurement for Patients with PsA,ACR12,QCDR Measure,Process,Y,32.073379709423335,61.44,1.18,6.45,31.87,45.24,63.16,67.11,79.31,85.23,90.44,94.15,No,No,1.18,6.45,31.87,45.24,63.16,67.11,79.31,85.23,90.44,94.15,98.99,N,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with arm, shoulder, or hand injury.",IROMS20,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,5.961123541011596,46.65,58.97,53.66,51.43,50.0,48.39,47.2,45.53,44.23,42.31,39.39,No,No,31.42,39.39,42.31,44.23,45.53,47.2,48.39,50.0,51.43,53.66,58.97,Y,y,registryMultiPerformanceRate
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,093,MIPS CQM,Process,Y,13.114064098523261,92.80,37.16,79.31,90.39,93.86,96.28,97.8,99.015,100.0,100.0,100.0,Yes,Yes,37.16,79.31,90.39,93.86,96.28,97.8,99.015,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Breast Cancer Screening,112,Medicare Part B Claims,Process,Y,24.36429273394898,80.25,2.55,43.62,64.55,75.82,83.43,89.12,94.97,98.35,100.0,100.0,No,No,2.55,43.62,64.55,75.82,83.43,89.12,94.97,98.35,100.0,100.0,100.0,N,n,singlePerformanceRate
Breast Cancer Screening,112,eCQM,Process,Y,25.64686615362017,50.99,0.27,9.23,27.56,39.42,48.18,54.84,60.57,66.82,73.31,82.05,No,No,0.27,9.23,27.56,39.42,48.18,54.84,60.57,66.82,73.31,82.05,99.48,N,n,singlePerformanceRate
Breast Cancer Screening,112,MIPS CQM,Process,Y,29.782212708813024,63.07,0.24,15.37,36.27,47.83,59.02,68.59,76.82,83.9,93.75,100.0,No,No,0.24,15.37,36.27,47.83,59.02,68.59,76.82,83.9,93.75,100.0,100.0,N,n,singlePerformanceRate
Functional Status Change for Patients with Shoulder Impairments,221,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,23.175112058831434,60.10,23.08,33.78,38.61,44.35,50.0,55.115,61.18,71.43,86.67,97.67,No,No,23.08,33.78,38.61,44.35,50.0,55.115,61.18,71.43,86.67,97.67,100.0,Y,n,singlePerformanceRate
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,MIPS CQM,Process,Y,3.096176104463253,98.96,82.445,97.68,99.18,99.785,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,82.445,97.68,99.18,99.785,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Foley catheter use in the emergency department,ACEP31,QCDR Measure,Process,Y,11.270547264912379,77.80,51.29,60.64,66.67,74.19,76.32,79.395,81.16,85.12,87.39,88.79,No,No,51.29,60.64,66.67,74.19,76.32,79.395,81.16,85.12,87.39,88.79,97.75,Y,n,registrySinglePerformanceRate
Venous Leg Ulcer (VLU) Healing or Closure,CDR6,QCDR Measure,Outcome,Y,12.14653964529034,23.97,2.56,8.67,17.15,19.1,20.78,21.73,23.39,27.58,32.31,37.04,No,No,2.56,8.67,17.15,19.1,20.78,21.73,23.39,27.58,32.31,37.04,65.94,Y,n,registryMultiPerformanceRate
Evidence of anatomic closure of macular hole within 90 days after surgery as documented by OCT,IRIS46,QCDR Measure,Outcome,Y,25.015819576830364,60.06,4.17,24.14,40.0,53.06,56.52,63.31,66.67,71.91,81.58,95.24,No,No,4.17,24.14,40.0,53.06,56.52,63.31,66.67,71.91,81.58,95.24,100.0,Y,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS11,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,7.013222451959964,48.10,60.71,56.0,53.4,51.52,50.0,48.94,47.62,45.65,43.45,40.0,No,No,27.91,40.0,43.45,45.65,47.62,48.94,50.0,51.52,53.4,56.0,60.71,Y,y,registryMultiPerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,MIPS CQM,Process,Y,11.041977605832598,90.57,56.91,77.92,82.845,86.67,90.0,93.24,96.235,100.0,100.0,100.0,No,No,56.91,77.92,82.845,86.67,90.0,93.24,96.235,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF ≤ 40%),007,eCQM,Process,Y,9.366406328444418,86.43,54.55,75.76,80.77,83.81,86.26,88.095,90.0,91.8,93.33,95.83,No,No,54.55,75.76,80.77,83.81,86.26,88.095,90.0,91.8,93.33,95.83,100.0,N,n,singlePerformanceRate
Melanoma Reporting,397,Medicare Part B Claims,Process,Y,2.365947174639051,98.91,90.62,95.16,98.44,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,90.62,95.16,98.44,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Melanoma Reporting,397,MIPS CQM,Process,Y,6.89563886362875,98.75,41.33,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,41.33,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Querying and Follow-Up About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease,AAN9,QCDR Measure,Process,Y,21.72886723192895,80.86,9.15,59.12,66.67,75.51,82.82,90.06,93.96,95.75,96.67,98.0,No,No,9.15,59.12,66.67,75.51,82.82,90.06,93.96,95.75,96.67,98.0,100.0,N,n,registrySinglePerformanceRate
Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,QCDR Measure,Process,Y,16.57948670759078,80.48,15.51,61.12,71.64,78.63,81.01,84.12,86.74,88.17,92.67,96.05,No,No,15.51,61.12,71.64,78.63,81.01,84.12,86.74,88.17,92.67,96.05,98.1,N,n,registrySinglePerformanceRate
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,QCDR Measure,Process,Y,6.499180372440321,92.76,65.18,86.49,89.515,91.49,92.025,93.1,93.93,96.25,98.19,100.0,No,No,65.18,86.49,89.515,91.49,92.025,93.1,93.93,96.25,98.19,100.0,100.0,N,n,registrySinglePerformanceRate
Obstructive Sleep Apnea: Mitigation Strategies,AQI68,QCDR Measure,Process,Y,15.951152681602327,91.41,29.01,75.39,86.71,93.27,96.2,98.52,99.35,99.79,99.99,100.0,Yes,Yes,29.01,75.39,86.71,93.27,96.2,98.52,99.35,99.79,99.99,100.0,100.0,Y,n,registrySinglePerformanceRate
Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation patients with low back pain measured via the validated Modified Low Back Pain Disability Questionnaire (MDQ) score.,IROMS17,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,7.6275653941685775,44.75,59.09,53.33,51.04,49.23,47.62,45.71,43.64,41.67,38.545,34.29,No,No,27.99,34.29,38.545,41.67,43.64,45.71,47.62,49.23,51.04,53.33,59.09,Y,y,registryMultiPerformanceRate
Melanoma: Coordination of Care,138,MIPS CQM,Process,Y,23.04551949953677,90.45,3.33,60.78,93.02,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,3.33,60.78,93.02,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Functional Status Change for Patients with Low Back Impairments,220,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,21.854787030116476,59.58,24.78,33.33,40.0,45.38,49.54,55.89,60.24,67.5,84.47,95.83,No,No,24.78,33.33,40.0,45.38,49.54,55.89,60.24,67.5,84.47,95.83,100.0,Y,n,singlePerformanceRate
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,ACEP19,QCDR Measure,Process,Y,12.989333181573947,78.97,53.96,58.89,65.07,72.47,77.57,81.87,85.25,87.73,91.04,94.09,No,No,53.96,58.89,65.07,72.47,77.57,81.87,85.25,87.73,91.04,94.09,99.07,Y,n,registrySinglePerformanceRate
Safe Hydroxychloroquine Dosing,ACR15,QCDR Measure,Process,Y,16.697610934175312,68.72,32.53,44.22,50.55,58.68,68.86,70.89,75.07,80.22,85.15,90.24,No,No,32.53,44.22,50.55,58.68,68.86,70.89,75.07,80.22,85.15,90.24,96.09,Y,n,registrySinglePerformanceRate
Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment,AQUA14,QCDR Measure,Outcome,Y,13.358575415921305,11.03,66.1,22.22,15.89,12.0,9.06,7.69,4.6,3.06,2.08,0.0,No,No,0.0,0.0,2.08,3.06,4.6,7.69,9.06,12.0,15.89,22.22,66.1,Y,y,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with arm, shoulder, and hand injury measured via the validated Disability of Arm Shoulder and Hand (DASH) score, Quick Disability of Arm Shoulder and Hand (QDASH) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS19,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,6.659495209561772,42.16,56.52,50.0,47.83,45.36,43.9,42.41,40.91,38.71,36.59,33.33,No,No,26.92,33.33,36.59,38.71,40.91,42.41,43.9,45.36,47.83,50.0,56.52,Y,y,registryMultiPerformanceRate
Arteriovenous Fistulae Thrombectomy Success Rate,RPAQIR15,QCDR Measure,Outcome,Y,9.525746989025308,83.38,60.47,71.15,74.24,79.41,81.48,85.29,86.47,90.24,91.24,93.1,No,No,60.47,71.15,74.24,79.41,81.48,85.29,86.47,90.24,91.24,93.1,100.0,Y,n,registrySinglePerformanceRate
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,MIPS CQM,Process,Y,7.600789319436629,96.74,67.35,88.0,95.45,98.55,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,67.35,88.0,95.45,98.55,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD),005,eCQM,Process,Y,14.840457087446268,77.20,24.0,60.8,68.89,73.61,77.43,80.03,82.39,85.53,88.14,91.67,No,No,24.0,60.8,68.89,73.61,77.43,80.03,82.39,85.53,88.14,91.67,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,eCQM,Process,Y,31.5761156670193,39.95,0.07,1.8,7.13,15.39,24.395,33.79,45.425,58.935,72.82,90.515,No,No,0.07,1.8,7.13,15.39,24.395,33.79,45.425,58.935,72.82,90.515,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,MIPS CQM,Process,Y,29.96178164431446,83.32,0.05,27.21,72.82,90.13,96.65,98.72,99.65,100.0,100.0,100.0,Yes,No,0.05,27.21,72.82,90.13,96.65,98.72,99.65,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Medicare Part B Claims,Process,Y,13.041959435582475,96.73,17.33,95.875,99.48,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,17.33,95.875,99.48,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Dementia: Functional Status Assessment,282,MIPS CQM,Process,Y,19.814747115127012,93.76,0.6,84.62,97.97,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.6,84.62,97.97,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia,286,MIPS CQM,Process,Y,11.754126082774008,96.75,33.33,93.07,99.32,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,33.33,93.07,99.32,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,MIPS CQM,Process,Y,22.1787874383887,90.61,1.77,77.38,91.3,96.3,97.72,98.7,99.44,100.0,100.0,100.0,Yes,Yes,1.77,77.38,91.3,96.3,97.72,98.7,99.44,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Medicare Part B Claims,Process,Y,21.449522641975683,90.93,15.22,75.0,92.73,96.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,15.22,75.0,92.73,96.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Patient-Centered Surgical Risk Assessment and Communication,358,MIPS CQM,Process,Y,33.287228526815255,81.46,0.5,9.26,66.01,93.75,98.4,99.76,100.0,100.0,100.0,100.0,Yes,Yes,0.5,9.26,66.01,93.75,98.4,99.76,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Perioperative Temperature Management,424,MIPS CQM,Outcome,Y,2.4530525365191047,99.27,88.68,98.46,99.64,99.9,99.98,100.0,100.0,100.0,100.0,100.0,Yes,Yes,88.68,98.46,99.64,99.9,99.98,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Otitis Media with Effusion (OME): Comprehensive Audiometric Evaluation for Chronic OME > or = 3 months,AAO21,QCDR Measure,Process,Y,30.5163977273469,51.90,1.14,13.73,19.46,35.0,37.5,51.64,71.13,77.27,83.58,91.3,No,No,1.14,13.73,19.46,35.0,37.5,51.64,71.13,77.27,83.58,91.3,95.0,N,n,registrySinglePerformanceRate
Intraoperative Antibiotic Redosing,AQI69,QCDR Measure,Process,Y,8.91807944479116,97.57,31.41,95.6,97.61,98.7,99.21,99.62,99.97,100.0,100.0,100.0,Yes,No,31.41,95.6,97.61,98.7,99.21,99.62,99.97,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Refractive Surgery: Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better within 30 days,IRIS23,QCDR Measure,Outcome,Y,19.622953242042698,78.15,24.29,44.0,68.55,77.58,81.25,82.35,84.21,89.2,94.29,100.0,No,No,24.29,44.0,68.55,77.58,81.25,82.35,84.21,89.2,94.29,100.0,100.0,Y,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with neck pain/injury.",IROMS16,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,8.280529901263765,48.24,63.41,55.77,53.85,52.24,51.22,50.0,47.83,45.73,43.84,40.0,No,No,25.35,40.0,43.84,45.73,47.83,50.0,51.22,52.24,53.85,55.77,63.41,Y,y,registryMultiPerformanceRate
Melanoma: Continuity of Care - Recall System,137,MIPS CQM,Structure,Y,14.734218985480046,95.79,15.56,92.16,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,No,No,15.56,92.16,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents,239,eCQM,Process,Y,17.566717089624603,40.53,3.25,25.73,29.79,31.71,33.13,34.48,37.98,43.76,52.67,66.56,No,No,3.25,25.73,29.79,31.71,33.13,34.48,37.98,43.76,52.67,66.56,94.04,N,n,multiPerformanceRate
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,MIPS CQM,Process,Y,21.36205140108089,91.72,2.94,73.13,92.105,98.79,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,2.94,73.13,92.105,98.79,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Functional Status Assessment for Total Hip Replacement,376,eCQM,Process,Y,16.640163259599422,14.08,0.47,1.995,2.58,3.45,4.1,5.955,10.4,15.76,22.92,44.045,No,No,0.47,1.995,2.58,3.45,4.1,5.955,10.4,15.76,22.92,44.045,61.54,Y,n,singlePerformanceRate
Osteoporosis Management in Women Who Had a Fracture,418,MIPS CQM,Process,Y,34.665981989575705,39.36,1.06,4.17,6.82,14.29,20.65,29.755,38.21,49.21,79.76,100.0,No,No,1.06,4.17,6.82,14.29,20.65,29.755,38.21,49.21,79.76,100.0,100.0,N,n,singlePerformanceRate
Age-Related Hearing Loss: Comprehensive Audiometric Evaluation,AAO16,QCDR Measure,Process,Y,14.050732043782753,93.52,23.26,82.07,93.37,95.09,97.41,98.35,99.82,100.0,100.0,100.0,Yes,Yes,23.26,82.07,93.37,95.09,97.41,98.35,99.82,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients failing to achieve a Minimal Clinically Important Difference (MCID) in improvement in pain score, measured via the Numeric Pain Rating Scale (NPRS), in rehabilitation patients with hip, leg or ankle (lower extremity except knee) injury.",IROMS14,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,6.826493213590456,47.42,60.61,55.0,52.55,50.96,50.0,48.15,46.43,45.0,42.86,39.13,No,No,26.9,39.13,42.86,45.0,46.43,48.15,50.0,50.96,52.55,55.0,60.61,Y,y,registryMultiPerformanceRate
Pneumococcal Vaccination Status for Older Adults,111,MIPS CQM,Process,Y,25.03905030496317,68.98,0.8,31.24,51.62,62.82,69.63,74.7,79.23,83.71,89.62,98.23,No,No,0.8,31.24,51.62,62.82,69.63,74.7,79.23,83.71,89.62,98.23,100.0,N,n,singlePerformanceRate
Pneumococcal Vaccination Status for Older Adults,111,Medicare Part B Claims,Process,Y,21.90971851331998,81.60,1.52,53.13,68.7,76.21,82.17,87.85,93.87,98.43,100.0,100.0,No,No,1.52,53.13,68.7,76.21,82.17,87.85,93.87,98.43,100.0,100.0,100.0,N,n,singlePerformanceRate
Assessment of Cognitive Impairment or Dysfunction for Patients with Parkinson's Disease,291,MIPS CQM,Process,Y,35.5658545652295,75.94,1.82,8.6,34.91,76.92,92.31,100.0,100.0,100.0,100.0,100.0,Yes,Yes,1.82,8.6,34.91,76.92,92.31,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,MIPS CQM,Process,Y,19.41826711442792,80.17,10.0,59.38,66.67,75.0,80.56,84.465,88.89,93.18,96.97,100.0,No,No,10.0,59.38,66.67,75.0,80.56,84.465,88.89,93.18,96.97,100.0,100.0,Y,n,singlePerformanceRate
Children Who Have Dental Decay or Cavities,378,eCQM,Outcome,Y,27.17685200778247,22.47,92.31,68.29,50.04,34.04,15.62,7.565,3.67,1.59,0.87,0.0,No,No,0.0,0.0,0.87,1.59,3.67,7.565,15.62,34.04,50.04,68.29,92.31,Y,y,singlePerformanceRate
HIV Screening,475,eCQM,Process,Y,14.33325627930457,17.66,0.13,3.005,5.83,8.82,11.8,14.62,17.96,21.74,26.425,34.675,No,No,0.13,3.005,5.83,8.82,11.8,14.62,17.96,21.74,26.425,34.675,71.81,N,n,singlePerformanceRate
Helicobacter pylori Status and Turnaround Time,CAP28,QCDR Measure,Process,Y,8.23317107087864,94.31,65.13,83.0,92.13,94.01,95.77,97.275,98.91,99.3,99.84,99.95,Yes,No,65.13,83.0,92.13,94.01,95.77,97.275,98.91,99.3,99.84,99.95,100.0,Y,n,registrySinglePerformanceRate
Upper Extremity Edema Improvement,RCOIR10,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,9.962249691656947,76.48,50.0,65.43,69.88,71.59,72.57,76.32,79.37,83.18,86.05,89.32,No,No,50.0,65.43,69.88,71.59,72.57,76.32,79.37,83.18,86.05,89.32,93.33,Y,n,registrySinglePerformanceRate
"Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments",219,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,20.729737857216573,55.77,16.42,34.0,37.5,41.67,47.56,51.465,56.49,60.67,74.07,95.24,No,No,16.42,34.0,37.5,41.67,47.56,51.465,56.49,60.67,74.07,95.24,100.0,Y,n,singlePerformanceRate
Dementia: Cognitive Assessment,281,eCQM,Process,Y,29.29060179716509,39.19,0.53,4.0,10.0,16.67,24.44,34.78,44.12,56.02,66.67,84.78,No,No,0.53,4.0,10.0,16.67,24.44,34.78,44.12,56.02,66.67,84.78,100.0,N,n,singlePerformanceRate
Lung Cancer Reporting (Resection Specimens),396,MIPS CQM,Process,Y,0.6494933090044567,99.95,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Anesthesiology Smoking Abstinence,404,MIPS CQM,Intermediate Outcome,Y,24.550918753395024,69.97,7.64,30.97,50.0,61.67,69.96,76.14,80.33,86.44,91.94,97.06,No,No,7.64,30.97,50.0,61.67,69.96,76.14,80.33,86.44,91.94,97.06,100.0,Y,n,singlePerformanceRate
Skin Cancer: Biopsy Reporting Time - Pathologist to Clinician,440,MIPS CQM,Process,Y,5.465421031521577,98.49,71.05,96.74,98.985,99.735,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,71.05,96.74,98.985,99.735,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Report Turnaround Time: Radiography,ACRAD15,QCDR Measure,Outcome,Y,5.283546921819953,3.13,33.72,5.24,3.61,2.71,2.21,1.77,1.53,1.26,1.01,0.72,No,No,0.27,0.72,1.01,1.26,1.53,1.77,2.21,2.71,3.61,5.24,33.72,Y,y,nonProportion
Patient-Reported Experience with Anesthesia,AQI48,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,3.8208178693690713,93.40,83.72,90.0,91.14,91.84,92.67,93.515,94.29,95.49,96.15,97.71,No,No,83.72,90.0,91.14,91.84,92.67,93.515,94.29,95.49,96.15,97.71,100.0,Y,n,registryMultiPerformanceRate
Advance Care Plan,047,Medicare Part B Claims,Process,Y,26.275227998552467,88.96,0.65,43.14,96.34,99.83,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.65,43.14,96.34,99.83,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Advance Care Plan,047,MIPS CQM,Process,Y,34.97570718676064,71.64,0.13,5.4,34.06,60.46,79.06,90.86,96.78,99.1,99.91,100.0,No,No,0.13,5.4,34.06,60.46,79.06,90.86,96.78,99.1,99.91,100.0,100.0,Y,n,singlePerformanceRate
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,MIPS CQM,Process,Y,25.041402785827078,87.03,0.62,49.57,80.13,92.91,98.65,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.62,49.57,80.13,92.91,98.65,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Cervical Cancer Screening,309,eCQM,Process,Y,22.816962735407486,36.44,0.44,7.77,15.59,21.88,27.955,34.04,40.17,46.99,54.55,68.52,No,No,0.44,7.77,15.59,21.88,27.955,34.04,40.17,46.99,54.55,68.52,95.18,N,n,singlePerformanceRate
Tobacco Use and Help with Quitting Among Adolescents,402,MIPS CQM,Process,Y,11.606953577300597,94.67,37.84,84.09,92.41,96.67,98.72,99.645,100.0,100.0,100.0,100.0,Yes,Yes,37.84,84.09,92.41,96.67,98.72,99.645,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Overuse of Imaging for the Evaluation of Primary Headache,419,MIPS CQM,Process,Y,18.160737645732784,10.92,68.04,37.82,16.48,8.86,6.21,2.975,0.59,0.0,0.0,0.0,Yes,No,0.0,0.0,0.0,0.0,0.59,2.975,6.21,8.86,16.48,37.82,68.04,Y,y,singlePerformanceRate
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,MIPS CQM,Process,Y,33.97341686652154,66.76,0.4,8.91,31.17,48.93,64.66,77.545,89.76,96.58,99.85,100.0,No,No,0.4,8.91,31.17,48.93,64.66,77.545,89.76,96.58,99.85,100.0,100.0,N,n,multiPerformanceRate
Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use,464,MIPS CQM,Process,Y,19.466369457249954,89.60,5.88,70.0,83.56,88.83,95.06,97.075,98.21,100.0,100.0,100.0,Yes,Yes,5.88,70.0,83.56,88.83,95.06,97.075,98.21,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Appropriate follow-up interval based on pathology findings in screening colonoscopy,GIQIC23,QCDR Measure,Process,Y,22.179149750241038,77.72,18.86,42.86,60.0,70.27,76.29,87.225,89.13,94.69,97.67,99.27,No,No,18.86,42.86,60.0,70.27,76.29,87.225,89.13,94.69,97.67,99.27,100.0,Y,n,registryMultiPerformanceRate
Visual Acuity Improvement Following Cataract Surgery and Minimally Invasive Glaucoma Surgery,IRIS55,QCDR Measure,Outcome,Y,18.280504840778658,39.13,3.7037,8.2734,27.2727,33.3333,33.6996,36.7347,43.9024,46.8697,48.8889,65.8537,No,No,3.7037,8.2734,27.2727,33.3333,33.6996,36.7347,43.9024,46.8697,48.8889,65.8537,90.0,Y,n,registryMultiPerformanceRate
Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stratify Thyroid Nodule Risk,MSN15,QCDR Measure,Process,Y,17.75162755772552,92.88,15.0,76.0,94.0,98.0,99.0,100.0,100.0,100.0,100.0,100.0,Yes,No,15.0,76.0,94.0,98.0,99.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,QCDR Measure,Process,Y,28.389686898192792,62.54,6.67,24.42,38.26,41.38,56.03,61.6,77.67,82.09,94.87,98.59,No,No,6.67,24.42,38.26,41.38,56.03,61.6,77.67,82.09,94.87,98.59,100.0,Y,n,registrySinglePerformanceRate
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,eCQM,Process,Y,19.10035315649298,87.51,3.88,68.62,83.13,88.69,91.94,94.165,96.08,97.66,98.96,100.0,No,No,3.88,68.62,83.13,88.69,91.94,94.165,96.08,97.66,98.96,100.0,100.0,N,n,singlePerformanceRate
Diabetes: Eye Exam,117,eCQM,Process,Y,38.28529298893326,54.86,0.59,5.9,13.82,23.0,33.26,46.04,80.51,97.65,99.21,100.0,No,No,0.59,5.9,13.82,23.0,33.26,46.04,80.51,97.65,99.21,100.0,100.0,N,n,singlePerformanceRate
Diabetes: Eye Exam,117,MIPS CQM,Process,Y,25.573788510153133,89.25,1.3,48.29,95.68,99.04,99.74,100.0,100.0,100.0,100.0,100.0,Yes,Yes,1.3,48.29,95.68,99.04,99.74,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,MIPS CQM,Process,Y,13.74099050893508,97.12,6.37,97.53,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,6.37,97.53,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,MIPS CQM,Process,Y,17.752933295156822,94.84,0.08,92.0,98.64,99.47,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.08,92.0,98.64,99.47,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Elder Maltreatment Screen and Follow-Up Plan,181,Medicare Part B Claims,Process,Y,18.939920673436678,94.57,0.37,94.03,99.61,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.37,94.03,99.61,100.0,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Use of High-Risk Medications in Older Adults,238,eCQM,Process,Y,5.27101976102259,3.38,21.82,10.55,6.7,3.84,1.79,0.64,0.16,0.0,0.0,0.0,Yes,No,0.0,0.0,0.0,0.0,0.16,0.64,1.79,3.84,6.7,10.55,21.82,Y,y,multiPerformanceRate
Use of High-Risk Medications in Older Adults,238,MIPS CQM,Process,Y,5.1659268606872315,1.34,20.0,3.73,0.625,0.05,0.0,0.0,0.0,0.0,0.0,0.0,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.05,0.625,3.73,20.0,Y,y,multiPerformanceRate
Psoriasis: Screening for Psoriatic Arthritis,AAD7,QCDR Measure,Process,Y,16.45141574061397,90.79,22.57,64.52,88.66,93.65,95.58,96.94,98.68,100.0,100.0,100.0,Yes,Yes,22.57,64.52,88.66,93.65,95.58,96.94,98.68,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Acute Anterior Uveitis: Post-treatment visual acuity,IRIS51,QCDR Measure,Outcome,Y,9.439470624281144,92.27,60.0,84.44,87.91,91.3,93.785,95.45,95.92,97.26,99.26,100.0,No,No,60.0,84.44,87.91,91.3,93.785,95.45,95.92,97.26,99.26,100.0,100.0,Y,n,registrySinglePerformanceRate
Complications After Cataract Surgery,IRIS54,QCDR Measure,Outcome,Y,2.0342004564227456,1.58,7.5,3.66,2.47,1.9,1.66,1.25,0.86,0.43,0.0,0.0,No,No,0.0,0.0,0.0,0.43,0.86,1.25,1.66,1.9,2.47,3.66,7.5,Y,y,registrySinglePerformanceRate
Anastomotic Leak Intervention,354,MIPS CQM,Outcome,Y,15.567599607468763,6.41,76.12,17.14,8.49,4.86,1.05,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,1.05,4.86,8.49,17.14,76.12,Y,y,singlePerformanceRate
Hospital admissions or infectious complications within 30 days of prostate biopsy,AQUA8,QCDR Measure,Outcome,Y,5.960702649136977,3.09,40.0,7.74,4.0,2.76,2.27,1.615,0.62,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.62,1.615,2.27,2.76,4.0,7.74,40.0,Y,y,registrySinglePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,MIPS CQM,Process,Y,32.21955426104372,54.52,0.53,7.51,19.66,32.59,44.63,57.44,69.25,79.69,87.68,97.77,No,No,0.53,7.51,19.66,32.59,44.63,57.44,69.25,79.69,87.68,97.77,100.0,N,n,singlePerformanceRate
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,Medicare Part B Claims,Process,Y,28.929027367675314,69.94,1.1,24.29,42.64,53.7,68.72,77.94,86.025,95.18,99.285,100.0,No,No,1.1,24.29,42.64,53.7,68.72,77.94,86.025,95.18,99.285,100.0,100.0,N,n,singlePerformanceRate
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,052,MIPS CQM,Process,Y,19.060344835305617,88.59,8.5,58.44,72.165,88.54,97.26,100.0,100.0,100.0,100.0,100.0,Yes,Yes,8.5,58.44,72.165,88.54,97.26,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,MIPS CQM,Process,Y,5.421037969497655,96.25,72.47,90.13,93.33,95.88,97.06,98.145,98.93,100.0,100.0,100.0,Yes,Yes,72.47,90.13,93.33,95.88,97.06,98.145,98.93,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Depression Remission at Twelve Months,370,eCQM,Outcome,Y,11.129292941369433,11.13,0.5181,1.9231,3.125,4.4693,5.9412,8.0,9.7288,12.1951,16.6667,24.6637,No,No,0.5181,1.9231,3.125,4.4693,5.9412,8.0,9.7288,12.1951,16.6667,24.6637,53.5714,Y,n,multiPerformanceRate
Immunizations for Adolescents,394,MIPS CQM,Process,Y,17.096523503598352,23.09,0.975,4.07,5.98,11.7,16.175,21.39,25.075,29.565,36.69,45.58,No,No,0.975,4.07,5.98,11.7,16.175,21.39,25.075,29.565,36.69,45.58,79.45,N,n,multiPerformanceRate
Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better),457,MIPS CQM,Outcome,Y,8.12928342450821,11.89,34.78,24.14,18.18,15.49,13.64,10.855,8.73,7.23,4.35,0.0,No,No,0.0,0.0,4.35,7.23,8.73,10.855,13.64,15.49,18.18,24.14,34.78,Y,y,singlePerformanceRate
"Multi-strata weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)",ACRAD34,QCDR Measure,Outcome,Y,12.613970440327664,88.12,36.6808,78.0275,83.1584,84.4009,90.0213,93.4405,94.9784,96.1203,96.1203,96.1203,No,No,36.6808,78.0275,83.1584,84.4009,90.0213,93.4405,94.9784,96.1203,96.1203,96.1203,100.0,Y,n,registryMultiPerformanceRate
Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH,AQUA26,QCDR Measure,Process,Y,24.125035791657552,7.06,95.93,0.03,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,Yes,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.03,95.93,Y,y,registrySinglePerformanceRate
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,eCQM,Process,Y,34.71331853751147,35.93,0.07,0.68,2.37,7.05,13.125,21.045,38.545,55.27,78.71,93.7,No,No,0.07,0.68,2.37,7.05,13.125,21.045,38.545,55.27,78.71,93.7,100.0,N,n,singlePerformanceRate
Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score – better),453,MIPS CQM,Process,Y,7.809308954378037,12.45,32.56,24.39,19.23,15.58,13.19,11.21,9.68,7.14,5.22,3.57,No,No,0.0,3.57,5.22,7.14,9.68,11.21,13.19,15.58,19.23,24.39,32.56,Y,y,singlePerformanceRate
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells,IRIS17,QCDR Measure,Outcome,Y,20.024482833887877,65.68,13.33,32.2,50.0,60.75,67.86,71.37,74.02,77.78,82.14,87.18,No,No,13.33,32.2,50.0,60.75,67.86,71.37,74.02,77.78,82.14,87.18,93.16,Y,n,registrySinglePerformanceRate
Improved Access Site Bleeding,RCOIR7,QCDR Measure,Outcome,Y,7.63655639300487,88.14,69.89,75.44,82.11,84.8,87.64,88.89,91.3,92.72,95.31,96.55,No,No,69.89,75.44,82.11,84.8,87.64,88.89,91.3,92.72,95.31,96.55,100.0,Y,n,registrySinglePerformanceRate
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,MIPS CQM,Outcome,Y,5.495498697438141,3.10,32.26,8.655,6.105,3.39,1.81,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,1.81,3.39,6.105,8.655,32.26,Y,y,singlePerformanceRate
Skin Cancer: Biopsy Reporting Time - Clinician to Patient,AAD6,QCDR Measure,Process,Y,14.650687445770703,94.67,30.86,88.73,94.82,98.51,99.46,100.0,100.0,100.0,100.0,100.0,Yes,Yes,30.86,88.73,94.82,98.51,99.46,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,QCDR Measure,Process,Y,18.70990980602245,81.97,25.0,50.56,64.885,79.63,82.14,89.66,92.195,95.52,97.985,100.0,No,No,25.0,50.56,64.885,79.63,82.14,89.66,92.195,95.52,97.985,100.0,100.0,N,n,registrySinglePerformanceRate
Functional Status Change for Patients with Knee Impairments,217,MIPS CQM,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,21.310417505107043,60.45,20.41,37.65,42.94,47.06,52.7,56.67,61.05,65.31,81.2,96.88,No,No,20.41,37.65,42.94,47.06,52.7,56.67,61.05,65.31,81.2,96.88,100.0,Y,n,singlePerformanceRate
Assessment of Mood Disorders and Psychosis for Patients with Parkinson's Disease,290,MIPS CQM,Process,Y,28.20816345967381,84.16,0.565,26.445,72.345,89.475,96.22,100.0,100.0,100.0,100.0,100.0,Yes,Yes,0.565,26.445,72.345,89.475,96.22,100.0,100.0,100.0,100.0,100.0,100.0,N,n,singlePerformanceRate
Rehabilitative Therapy Referral for Patients with Parkinson's Disease,293,MIPS CQM,Process,Y,32.90148679224138,74.90,0.79,17.33,36.84,68.97,86.36,92.96,98.55,100.0,100.0,100.0,No,No,0.79,17.33,36.84,68.97,86.36,92.96,98.55,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Oncology: Supportive Care Drug Utilization in Last 14 Days of Life,PIMSH9,QCDR Measure,Efficiency,Y,5.866501944410271,7.60,25.0,15.6,12.1,10.0,8.3,6.8,4.8,4.1,3.2,0.0,No,No,0.0,0.0,3.2,4.1,4.8,6.8,8.3,10.0,12.1,15.6,25.0,Y,y,registrySinglePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001,eCQM,Intermediate Outcome,Y,27.04511066886456,46.35,99.52,93.33,75.0,57.6,46.15,38.165,32.26,27.32,22.5,17.07,No,No,6.25,17.07,22.5,27.32,32.26,38.165,46.15,57.6,75.0,93.33,99.52,Y,y,singlePerformanceRate
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),001,MIPS CQM,Intermediate Outcome,Y,28.54452983862189,34.00,99.0,90.0,80.0,70.0,60.0,50.0,40.0,30.0,20.0,10.0,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,y,singlePerformanceRate
Controlling High Blood Pressure,236,eCQM,Intermediate Outcome,Y,17.32446823792854,62.30,2.74,41.96,51.36,56.61,60.71,64.235,67.55,71.1,75.28,81.35,No,No,2.74,41.96,51.36,56.61,60.71,64.235,67.55,71.1,75.28,81.35,97.46,Y,n,singlePerformanceRate
Controlling High Blood Pressure,236,Medicare Part B Claims,Intermediate Outcome,Y,18.268291541644512,76.30,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,n,singlePerformanceRate
Controlling High Blood Pressure,236,MIPS CQM,Intermediate Outcome,Y,19.96793773042928,68.96,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,No,No,1.0,10.0,20.0,30.0,40.0,50.0,60.0,70.0,80.0,90.0,99.0,Y,n,singlePerformanceRate
Unplanned Reoperation within the 30 Day Postoperative Period,355,MIPS CQM,Outcome,Y,7.339453018272936,2.55,40.0,8.6,2.7,1.08,0.0,0.0,0.0,0.0,0.0,0.0,No,No,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.08,2.7,8.6,40.0,Y,y,singlePerformanceRate
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,MIPS CQM,Intermediate Outcome,Y,15.682460213032051,94.23,22.73,81.45,95.75,99.53,100.0,100.0,100.0,100.0,100.0,100.0,No,No,22.73,81.45,95.75,99.53,100.0,100.0,100.0,100.0,100.0,100.0,100.0,Y,n,singlePerformanceRate
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,eCQM,Process,Y,11.289709185518785,73.08,32.98,60.84,66.645,69.78,72.385,74.61,76.62,78.79,81.415,84.75,No,No,32.98,60.84,66.645,69.78,72.385,74.61,76.62,78.79,81.415,84.75,91.92,N,n,singlePerformanceRate
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,MIPS CQM,Process,Y,16.472568781088363,82.01,20.5,62.01,70.7,76.65,79.88,83.95,87.63,91.78,100.0,100.0,No,No,20.5,62.01,70.7,76.65,79.88,83.95,87.63,91.78,100.0,100.0,100.0,N,n,singlePerformanceRate
Report Turnaround Time: CT,ACRAD18,QCDR Measure,Outcome,Y,8.079126463185279,4.32,41.65,10.11,3.86,2.8,2.33,2.01,1.66,1.36,1.11,0.78,No,No,0.32,0.78,1.11,1.36,1.66,2.01,2.33,2.8,3.86,10.11,41.65,Y,y,nonProportion
Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA),AQI56,QCDR Measure,Process,Y,8.249152868775795,97.25,66.67,93.12,95.53,98.05,99.55,99.905,100.0,100.0,100.0,100.0,Yes,Yes,66.67,93.12,95.53,98.05,99.55,99.905,100.0,100.0,100.0,100.0,100.0,Y,n,registrySinglePerformanceRate
"Failure to Progress (FTP): Proportion of patients not achieving a Minimal Clinically Important Difference (MCID) to indicate functional improvement in rehabilitation of patients with hip, leg or ankle injuries using the validated Lower Extremity Function Scale (LEFS) score, or equivalent instrument which has undergone peer reviewed published validation and demonstrates a peer reviewed published MCID.",IROMS13,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,7.429178741940686,44.87,61.11,53.57,50.0,48.61,47.43,45.67,43.75,41.46,38.46,34.78,No,No,28.57,34.78,38.46,41.46,43.75,45.67,47.43,48.61,50.0,53.57,61.11,Y,y,registryMultiPerformanceRate
Oncology: Patient-Reported Pain Improvement,PIMSH4,QCDR Measure,Patient-Reported Outcome-Based Performance Measure (PRO-PM),Y,11.783113977213327,42.72,13.3,28.4,34.15,37.5,39.65,42.2,44.65,48.2,51.8,57.1,No,No,13.3,28.4,34.15,37.5,39.65,42.2,44.65,48.2,51.8,57.1,72.2,Y,n,registrySinglePerformanceRate
